European Study of HF0220 in Mild to Moderate Alzheimer's Disease Patients
- Registration Number
- NCT00357357
- Lead Sponsor
- Hunter-Fleming Ltd
- Brief Summary
The purpose of this Phase II study is to evaluate the safety and tolerability of HF 0220 in patients with Alzheimer's disease compared to placebo (inactive substance). The study will also validate biochemical markers as appropriate clinical end-points and to assess the suitability of chosen dose levels for future clinical studies.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Group1 HF0220 4x 7 day rising dose Group3 HF0220 28 day fixed lower dose Group4 HF0220 28 day fixed upper dose Group2 HF0220 4x, 7 day rising dose
- Primary Outcome Measures
Name Time Method Safety/tolerability of HF 0220 in mild to moderate Alzheimer's patients June 2008
- Secondary Outcome Measures
Name Time Method Validate biochemical markers relevant to Alzheimer's disease June 2008 Assess the suitability of chosen HF0220 dose levels for future studies June 2008
Trial Locations
- Locations (10)
King George Hospital
🇮🇳Visakhapatnam, Andh Prad, India
Madras Medical College & Government General Hospital
🇮🇳Chennai, Tamilnadu, India
Sree Chitra Tirunal Institute for Medical Sciences and Technology
🇮🇳Thiruvananthapuram, Kerala, India
Research Institute for Care of the Elderly
🇬🇧Bath, United Kingdom
Memory Assessment and Research Centre
🇬🇧Southampton, United Kingdom
Kingshill Research Centre
🇬🇧Swindon, United Kingdom
Karolinksa Institute
🇸🇪Stockholm, Sweden
Manipal Hospital,
🇮🇳Bangalore, Karna, India
Malmo University Hospital
🇸🇪Malmo, Sweden
Nizam's Institute of Medical Sciences,
🇮🇳Hyderabaad, Panjagutta, India